Patient-Reported Outcomes Guidance Needs Flexibility, Industry Tells FDA
Executive Summary
FDA's draft guidance on patient-reported outcomes (PROs) should offer both greater flexibility and detail, industry commenters told the agency
You may also be interested in...
FDA's Final PRO Guidance Grounds Policy With More Details
Issued in December, the final guidance explains "content validity," and advises sponsors to use target product profiles and to document that patient input informed PRO instrument development.
FDA's Final PRO Guidance Grounds Policy With More Details
FDA's final guidance on patient-reported outcomes measurements adds more detail and information on practical application to the draft guidance issued several years ago - in keeping with the comments made on the draft
FDA's Final PRO Guidance Grounds Policy With More Details
FDA's final guidance on patient-reported outcomes measurements adds more detail and information on practical application to the draft guidance issued several years ago - in keeping with the comments made on the draft